A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma
Cancer Multiple Myeloma
For the latest version of this information please go to www.forpatients.roche.com